Protocol Ledger

NCT03737214 · Phase III · COMPLETED

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Interventional Phase III clinical trial protocol NCT03737214 sponsored by Idorsia Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-18 Enrollment: 107 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03737214
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)107 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03737214
Protocol FieldVerified Registry Value
NCT IdentifierNCT03737214
Consolidated Lead SponsorIdorsia Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment107 participants (ACTUAL)
Registered Start Date2018-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI